Direct renin inhibitor aliskiren - new opportunities of kidney protection at hypertensive patients


Cite item

Full Text

Abstract

The interest to direct pharmacological active renin blockade is explained by the need of its homodynamic and tissue effects removing, that are realized mostly through interaction with pro-renin receptors. Renin activity control provides the effective control of the activity of the most RAAS components. Direct renin inhibitor aliskiren with proven in large clinical trials efficacy can be especially effective at hypertensive patients for kidney injury prevention

References

  1. Пальцев М.А., Серов В.В. Эндокринная система почек и нефрогенная гипертензия // Терапевтический архив. 1987. № 8. С. 110-113.
  2. Пальцев М.А., Серов В.В. Почки и артериальная гипертензия. М., 1993.
  3. Stella A, Zanchetti A. Control of renal renin release. Kidney Int 1987;31(Suppl. 20):89-94.
  4. Persson PB. Renin: origin, secretion and synthesis. J Physiol 2003;552(3):667-71.
  5. Chen M, Schnermann J, Smart AM, et al. Cyclic AMP selectively increases renin mRNA stabilityin cultured juxtaglomerular granular cells. J Biol Chem 1993;268:24138-44.
  6. Friis UG, Jensen BL, Sethi S, et al. Control of renin secretion from rat juxtaglomerular cells by cAMP-specific phosphodiesterases. Circ Res 2002;90:996-1003.
  7. Friis UG, Jorgensen F, Andreasen D, et al. Molecular and functional identification of cyclic AMP-sensitive BKCa potassium channels (ZERO variant) and L-type voltagedependent calcium channels in single rat juxtaglomerular cells. Circ Res 2003;93:213-20.
  8. Kurtz A, Della Bruna R, Pfeilschifter J, et al. Atrial natriuretic peptide inhibits renin release from juxtaglomerular cells by a cGMP-mediated process. Proc Natl Acad Sci USA 1986;83(13):4769-73.
  9. Skott O. Renin. Am J Physiol Regul Integr Comp Physiol 2002;282:R937-R939.
  10. Rummery NM, Hill CE. Vascular gap junctions and implications for hypertension. Clin Exp Pharmacol Physiol 2004;31(10):659-67.
  11. Wagner C. Function of connexins in the renal circulation. Kidney Int 2008;3(5):547-55.
  12. Gomez RA, Sequeira Lopez ML. Who and where is the renal baroreceptor?: the connexin hypothesis. Kidney Int 2009;75(5):460-62.
  13. Krop M, Danser AHJ. Circulating versus tissue angiotensin system: on the origin of (pro)renin. Curr Hypertens Rep 2008;10:112-18.
  14. Nguyen G, Delarue F, Burckle C, et al. Pivotal role of the renin/pro-renin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002;109:1417-27.
  15. Jan Danser AH, Batnburg WW, van Esch JHM. Prorenin and the (pro)renin receptor - an update. Nephrol Dial Transplant 2007;22:1288-92.
  16. Kaneshiro Y, Ichihara A, Sacoda M, et al. Slowly progressive, angiotensin II-independent glomerulosclerosis in human pro(renin) receptor-transgenic rats. J Am Soc Nephrol 2007;18:1789-95.
  17. Danser AHJ, Deinum J. Renin, prorenin, and the putative prorenin receptor. Hypertension 2005;46:1069-76.
  18. Oliver JA. Receptor mediated actions of renin and pro-renin. Kidney Int 2006;69:13-15.
  19. Huang Y, Wongamorntham S, Kasting J, et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006;69:105-13.
  20. Sakoda M, Ichihara A, Kaneshiro Y, et al. (Pro)renin receptor-mediated activation of mitogenactivated protein kinases in human vascular smooth muscle cells. Hypertens Res 2007;30:1139-46.
  21. Nguen G, Danser AHJ. Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents. Exp Physiol 2008;93(Pt.5):557-63.
  22. Ichihara A, Suzuki F, Nakagawa T, et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 2006;17:1950-61.
  23. Takahashi H, Ichihara A, Kaneshiro Y, et al. Regression of nephropathy developed in diabetes by (Pro)renin receptor blockade. J Am Soc Nephrol 2007;18:2054-61.
  24. Kaneshiro Y, Ichihara A, Sakoda M, et al. Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)rennin receptor-transgenic rats. J Am Soc Nephrol 2007;18:1789-95.
  25. Krebs C, Hamming I, Sadaghiani S, et al. Antihypertensive therapy upregulates renin and (pro)renin receptor in the clipped kidney of Goldblatt hypertensive rats. Kidney Int 2007;72:725-30.
  26. Fisher NDL, Hollenberg NK. Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol 2005;16:592-99.
  27. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006;368:1449-56.
  28. Kleinert HD, Martin D, Chekal MA, et al. Effects of renin inhibitor A-64662 in monkeys and rats with varying baseline plasma renin activity. Hypertension 1988;11:613-19.
  29. Himmelmann A, Bergbrant A, Svensson A, et al. Remikiren (Ro 42-5892) - an orally active renin inhibitor in essential hypertension. Effects on blood pressure and the renin-angiotensin-aldosterone system. Am J Hypertens 1996;9:517-22.
  30. Nussberger J, Wuerzner G, Jensen C, et al. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalapril. Hypertension 2002;39:e1-e8.
  31. Azizi M, Menard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004;15:3126-33.
  32. Fisher ND, Jan Danser AH, Nussberger J, et al. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008;117(25):3199-05.
  33. Oh B-H, Mitchell J, Herron JR, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24hur blood pressure control in patients with hypertension. J Am Coll Cardiol 2007;49:1157-63.
  34. Dahlof B, Anderson DR, Arora V, et al. Aliskiren, a direct renin inhibitor, provides antihypertensive efficacy and excellent tolerability independent of age or gender in patients with hypertension (abstr). J Clin Hypertens 2007;9(Suppl. A):A157.
  35. Schmieder RE, Philipp T, Guerediaga J, et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren. a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009;119:417-25.
  36. Luetscher JA, Kraemer FB, Wilson DM, et al. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular comlications. N Engl J Med 1985;312:1412-17.
  37. Chiarelli F, Pomilio M, De Luca FA, et al. Plasma prorenin levels may predict persistent microalbuminuria in children with diabetes. Pediatr Nephrol 2001;16:116-20.
  38. Kelly DJ, Zhang Y, Moe G, et al. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007;50(11):2398-04.
  39. Pilz B, Shagdarsuren E, Wellner M, et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005;46(3):569-76.
  40. Persson F, Rossing P, Schjoedt KJ, et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 2008;73(12):1419-25.
  41. Parving HH, Persson F, Lewis JB, et al. AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358(23):2433-46.
  42. Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the Direct Renin Inhibitor Aliskiren, Either Alone or in Combination With Losartan, Compared to Losartan, on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy: The Aliskiren Left Ventricular Assessment of Hypertrophy (ALLAY) Trial. Presented at the American College of Cardiology, 57th Annual Scientific Session, March 31st, 2008.
  43. McMurray JJV, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circulation-Heart Failure 2008;1:17-24.
  44. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009 Jan 14. [Epub ahead of print] 1 of 9.
  45. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361(9352):117-24.
  46. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372(9638):547-53.
  47. Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomiased. Double-blind trial. Lancet 2007;370:221-29.
  48. Vaidyanathan S, Bigler H, Yeh C, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet 2007;46(8):661-75.
  49. Mooser V, Nussberger J, Juillerat L, et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 1990;15(2):276-82.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies